^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® Master Panel

    Company:
    Amoy Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    4ms
    Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC (IASLC-WCLC 2024)
    Conclusions : Genomic and transcriptomic biomarkers of tissue and peripheral blood were discovered. These biomarkers displayed association with clinical benefit of adebrelimab plus chemotherapy and adebrelimab with consolidate TRT, but further verification was warranted.
    Retrospective data • Clinical • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1)
    |
    TP53 mutation • TMB-H • RB1 mutation
    |
    AmoyDx® Master Panel
    |
    Ariely (adebrelimab)
    4ms
    Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing (ESMO 2024)
    This study demonstrated that Amoydx human homologous recombination repair gene panel exhibited high concordance with AmoyDx master panel and could provide reliable HRR SNV/Indel/HD detection.
    PARP Biomarker • BRCA Biomarker • Next-generation sequencing
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    AmoyDx® Master Panel
    |
    paclitaxel
    6ms
    Integrated analysis of DNA and RNA revealed PARPi resistant mechanism of ovarian cancer: A paired tissue analysis of pre and post PARPi therapy (ESMO-GC 2024)
    Resistance mechanism of PARPi is complex. BRCA restoration mutation is a frequent cause of PARPi resistance. PARPi resistance could be driven without DNA mutation.
    Tumor mutational burden • PARP Biomarker • BRCA Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • CCND1 (Cyclin D1) • BRCA (Breast cancer early onset)
    |
    AmoyDx® HRD Focus Panel • AmoyDx® Master Panel
    over1year
    Resistance mechanism and microenvironment changes after PARPi treatment: Paired analysis of ovarian cancer samples pre and post treatment. (ASCO 2023)
    Our small-scale study confirmed that BRCA reversion mutation is one of the important resistance mechanisms of PARPi, and the reversion mutation is located near the germline pathogenic mutation to counteract the reading frame change caused by the frameshift mutation. The up-regulation of B-cell receptor, NK cytotoxic cytokine receptor interaction and other related pathways suggested that PARPi may activate immune response, and the changes in the levels of memory B cells, C7 and neutrophils also confirmed the results above. Epithelial mesenchymal transition induced by CCL18 may also lead to PARPi resistance and activate the NF-κb pathway simultaneously, increasing the inflammatory characteristics of TME.
    Tumor mutational burden • PARP Biomarker • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BRCA (Breast cancer early onset) • NGFR (Nerve Growth Factor Receptor) • CCL18 (C-C Motif Chemokine Ligand 18) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    MYC amplification • BRCA mutation • NGFR expression
    |
    AmoyDx® HRD Focus Panel • AmoyDx® Master Panel
    almost2years
    Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma (clinicaltrials.gov)
    P=N/A; N=60; Completed; Sponsor:Zhejiang University
    New trial
    |
    AmoyDx® Master Panel
    over2years
    AmoyDx® Master Panel--Study reveals clinically relevant intertumoral heterogeneity of NSCLCs driven by MET Exon 14 skipping mutation (AmoyDx Press Release)
    "A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping)...All the samples were subjected to targeted RNA sequencing using the AmoyDx® Master Panel consisting of 2660 onco-immunology genes."
    Clinical data
    |
    AmoyDx® Master Panel